Analysis
October's IPO market has a split personality by sector, based on figures tracked on Pulse's stats page. Iambic Therapeutics posted an 18.19% first-day pop after its offering priced, and City Therapeutics priced a separate $200 million biotech IPO in the same stretch -- real, bounded deals that cleared the window cleanly. Meanwhile the IPOs the broader market is actually waiting on, Anthropic and OpenAI, remain private, with reported target valuations as high as $2 trillion and roughly $1 trillion respectively still unconfirmed by either company.
## Two different IPO markets, same calendar The biotech deals pricing now share a common trait: they're small enough for investors to fully underwrite in weeks, with clinical data, revenue lines, or FDA pathways that bankers can diligence against established comparables. Anthropic and OpenAI are the opposite case -- IPOs so large, and businesses moving so fast, that no comparable-company analysis fully applies, which is part of why both have stayed in confidential-filing limbo through multiple reported timeline slips this year.
“That split means the current run of successful biotech pricings is a weak signal for how the AI megacaps will actually be received when they do list.”
That split means the current run of successful biotech pricings is a weak signal for how the AI megacaps will actually be received when they do list. A market willing to reward a $200 million biotech offering with a clean pricing isn't the same market that has to decide whether a $2 trillion valuation for Anthropic is defensible, or whether OpenAI's roughly $1 trillion target reflects its growth or its hype.
When the AI megacaps do finally list, they'll be tested by a market that's currently showing real appetite for bounded, auditable offerings -- and comparatively little tolerance for projects still built mostly on a pipeline chart, the same dynamic that just cost Firmus Grid its $30 billion data-center listing.
For growth and late-stage investors, the lesson isn't that AI is cooling -- it's that the IPO window rewards proof over scale right now, and a $200 million biotech deal with real data clears that bar more easily than a trillion-dollar AI company whose revenue curve is still mostly a projection.